145 related articles for article (PubMed ID: 7903917)
1. Cladribine for the treatment of hematologic malignancies.
Baltz JK; Montello MJ
Clin Pharm; 1993 Nov; 12(11):805-13; quiz 860-2. PubMed ID: 7903917
[TBL] [Abstract][Full Text] [Related]
2. Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia.
Rai KR
Semin Oncol; 1998 Jun; 25(3 Suppl 7):19-22. PubMed ID: 9671325
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
4. Cladribine: from the bench to the bedside--focus on hairy cell leukemia.
Greyz N; Saven A
Expert Rev Anticancer Ther; 2004 Oct; 4(5):745-57. PubMed ID: 15485311
[TBL] [Abstract][Full Text] [Related]
5. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.
Bryson HM; Sorkin EM
Drugs; 1993 Nov; 46(5):872-94. PubMed ID: 7507037
[TBL] [Abstract][Full Text] [Related]
6. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
Fabianowska-Majewska K; Wyczechowska D
Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193
[TBL] [Abstract][Full Text] [Related]
7. The role of cladribine in the treatment of lymphoid malignancies.
Nelson MC; Hogan DK
Oncol Nurs Forum; 1995 Oct; 22(9):1395-400. PubMed ID: 8539180
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
[TBL] [Abstract][Full Text] [Related]
9. 2-Chlorodeoxyadenosine in haematological malignancies.
Castaigne S
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):13-4. PubMed ID: 8099730
[TBL] [Abstract][Full Text] [Related]
10. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
11. Cladribine: not just another purine analogue?
Spurgeon S; Yu M; Phillips JD; Epner EM
Expert Opin Investig Drugs; 2009 Aug; 18(8):1169-81. PubMed ID: 19604118
[TBL] [Abstract][Full Text] [Related]
12. [Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia].
Terasaki Y; Okumura H; Hirose A; Ishiura Y; Yokawa S; Saito K; Nakao S
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1885-8. PubMed ID: 18030031
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group.
Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y
Jpn J Clin Oncol; 1997 Jun; 27(3):146-53. PubMed ID: 9255268
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of hairy cell leukemia with cladribine].
Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B
Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550
[TBL] [Abstract][Full Text] [Related]
15. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.
Montillo M; Tedeschi A; O'Brien S; Di Raimondo F; Lerner S; Ferrajoli A; Morra E; Keating MJ
Cancer; 2003 Jan; 97(1):114-20. PubMed ID: 12491512
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
18. High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies.
Van Den Neste E; Michaux L; Layios N; Costantini S; Francart J; Lambert C; Sonet A; André M; Robert A; Ferrant A
Ann Hematol; 2004 Jun; 83(6):356-63. PubMed ID: 15024607
[TBL] [Abstract][Full Text] [Related]
19. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Robak T
Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
[TBL] [Abstract][Full Text] [Related]
20. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies.
Laurencet FM; Zulian GB; Guetty-Alberto M; Iten PA; Betticher DC; Alberto P
Br J Cancer; 1999 Mar; 79(7-8):1215-9. PubMed ID: 10098762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
